Flibanzerin

{{Drugbox-lat | verifiedrevid = 437139289 | IUPAC_name = 1-(2-{4-[3-(trifluorometil)fenil]piperazin-1-il}etil)-1,3-dihidro-2H-benzimidazol-2-on | image = Flibanserin-structural.svg | width = | image2 = | width2 =

| tradename = | pregnancy_category = | legal_status = Nije kontrolisan | routes_of_administration = Oralno

| bioavailability = | metabolism = | elimination_half-life = | excretion =

| C=20 | H=21 | F=3 | N=4 | O=1 | molecular_weight = 390,40 g/mol | smiles = FC(F)(F)c4cc(N3CCN(CCN2c1ccccc1NC2=O)CC3)ccc4 | StdInChI_Ref = ^Y | StdInChI = 1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28) | StdInChIKey_Ref = ^Y | StdInChIKey = PPRRDFIXUUSXRA-UHFFFAOYSA-N }}

Flibanserin (BIMT-17, Girosa) je lek koji je razvila kompanija Beringer Ingelhajm kao nehormonski tretman za žene pre menopoze sa poremećajem hipoaktivne seksualne želje.^[1]^[2] Razvoj je prekinut oktobra 2010, nakon što je FDA objavila negativan izveštaj.^[3]

Reference

^ Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002). „Pharmacology of flibanserin”. CNS Drug Rev. 8 (2): 117—142. PMID 12177684. doi:10.1111/j.1527-3458.2002.tb00219.x.
^ Jolly E; Clayton A; Thorp J; Lewis-D’Agostino D; Wunderlich G; Lesko L (2008). „Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD)”. Sexologies. 17 (Suppl 1): S133—4. doi:10.1016/S1158-1360(08)72886-X.
^ Spiegel online: Pharmakonzern stoppt Lustpille für die Frau, 8 October 2010 (in German)

Vidi još

Spoljašnje veze

Vijagra za žene?
Marazziti D; Palego L; Giromella A; et al. (2002). „Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain”. Int. J. Neuropsychopharmacol. 5 (2): 131—40. PMID 12135537. doi:10.1017/S1461145702002869.
Podhorna J, Brown RE (2000). „Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety”. Br J Pharmacol. 130 (4): 739—746. PMC 1572126  . PMID 10864879. doi:10.1038/sj.bjp.0703364. Архивирано из оригинала 06. 01. 2013. г. Приступљено 10. 04. 2012.
Brambilla A, Baschirotto A, Grippa N, Borsini F (1999). „Effect of flibanserin (BIMT 17), fluoxetine, 8-OH-DPAT and buspirone on serotonin synthesis in rat brain”. Eur Neuropsychopharmacol. 10 (1): 63—7. PMID 10647099. doi:10.1016/S0924-977X(99)00056-5.

[1] Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002). „Pharmacology of flibanserin”. CNS Drug Rev. 8 (2): 117—142. PMID 12177684. doi:10.1111/j.1527-3458.2002.tb00219.x.

[2] Jolly E; Clayton A; Thorp J; Lewis-D’Agostino D; Wunderlich G; Lesko L (2008). „Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD)”. Sexologies. 17 (Suppl 1): S133—4. doi:10.1016/S1158-1360(08)72886-X.

[spon-3] Spiegel online: Pharmakonzern stoppt Lustpille für die Frau, 8 October 2010 (in German)

[1]

[2]

[3]